tsn084
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 18, 2022 (NCT05300438)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CDK19 inhibitor
- Cell division protein kinase 8INHIBITOR
CDK8 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06386705 | Phase 1 | Jul 20, 2022 | Chinese Academy of Medical Sciences, Tyligand Bioscience (Shanghai) Limited |
| NCT05300438 | Phase 1 | Feb 18, 2022 | Tyligand Bioscience (Shanghai) Limited, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tyligand Bioscience (Shanghai) Limited | For profit | 2 | 2 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1